81 studies on GHRP-6 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 160 published GHRP-6 COA source records from third-party laboratories, covering 75 publicly attributable vendor identities. Across 149 records with positive numeric purity, the arithmetic mean is 99.51%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 17 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-05. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $5.00 | $5.00–$5.00 | $1.00 | 1 source · 1 offer |
| 10 mg | $7.00 | $6.50–$7.50 | $0.70 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-05. Aggregate calculated: 2026-10-19T03:55:46.239772+00:00. Calculation time is not a laboratory observation date.
Within that total, 32 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 10 | 99.64% | 0 of 10 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 9 | 99.64% | 0 of 9 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 4 | 99.55% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #118688 (99.83%) · #116849 (99.52%) · #116257 (99.58%) · #114778 (99.6%) · #114888 (99.47%) · #115762 (99.43%)
This study introduces aza-Isotryptophan as a novel and versatile building block for peptide chemistry, significantly expanding the chemical space available for designing new peptide-based drugs. The ability of azaItr-…
This automated system significantly enhances the capabilities of anti-doping programs. By enabling reliable, quantitative analysis from Dried Blood Spot samples, it makes collection less invasive and sample handling m…
**Clinicians managing thalassemia-related growth failure** should note that standard stimulation testing may miss subnormal ultradian GH secretion, meaning affected patients could benefit from secretagogue-based proto…
**Continuous or prolonged central exposure to GH secretagogues drives desensitization**, not sensitization — a direct challenge to the assumption that chronic dosing linearly amplifies GH output. For peptide users and…
**Clinicians and researchers evaluating GH axis function** may have a meaningful alternative to the hypoglycemia-inducing ITT already in view: the **GHRH + GHRP-6 combination at saturating doses** is flagged as the mo…
**The central mechanism of GH secretagogues does not depend on intact noradrenergic circuitry**, which has direct implications for clinical and research contexts in which noradrenergic tone is altered — such as stress…
**GHRPs — particularly hexarelin — should be understood as direct cardiac agents**, not merely GH secretagogues; clinicians and researchers evaluating these compounds for body composition or GH-axis support must accou…
The study successfully identified adenosine as a partial agonist of the GHS-R, meaning it can activate the receptor but not to its full potential. Activation of GHS-R by adenosine was significantly inhibited by select…
**The identification of `GPR38` as a GHS-R family member with motilin as its ligand** reveals that GH secretagogue pharmacology is entangled with gut-motility signaling — a consideration for clinicians and researchers…
**Peptidyl GHS compounds like hexarelin may carry direct anticancer activity in lung carcinoma independent of their GH-releasing function**, a mechanistic split with major implications for therapeutic development and …
**GHS compounds including GHRP-2, GHRP-6, and MK-677 target four converging GH-axis nodes simultaneously**, which explains their superior efficacy over single-mechanism secretagogues and provides a pharmacological rat…
**The type of GHSR agonist chosen determines not just direct receptor activation but also how the body's own ghrelin pulses are amplified or suppressed.** For clinicians and researchers, this means MK-677's pharmacolo…
**Identifying a shared TM-III/TM-VI hotspot across peptide and nonpeptide GHSR agonists** means that medicinal chemistry efforts can converge on this core cleft rather than treating each chemotype as starting from scr…
**The ago-allosteric model for MK-677 and GHRP-6 is not supported in this assay system** — meaning assumptions about synergistic or supra-additive effects when combining ghrelin-pathway compounds with these secretagog…
**NN703 demonstrates that oral GH secretagogue therapy is pharmacologically viable**, with a 30% bioavailability and 4.1-hour half-life that are compatible with once-daily dosing — a profile ipamorelin itself cannot a…
**The practical takeaway for clinicians and researchers is that GHS peptides ipamorelin and GHRP-6 stimulate bone growth in adult female rats, but the mechanism is periosteal/dimensional expansion rather than increase…
This study reveals a critical GH-independent mechanism by which GHSs can increase body fat, potentially driven by increased feeding and altered metabolic signaling. This finding is highly significant for understanding…
This research provides a crucial mechanistic insight into how GHRPs stimulate growth hormone release, suggesting a significant interaction with the body's endogenous ghrelin system. Understanding this pathway could le…
**Chronic ipamorelin pretreatment uniquely sensitises the pituitary somatotroph population** to respond to subsequent GHS or GHRH stimulation — a 'priming' phenomenon that does not occur after equivalent chronic GHRH …
**Sustained, multi-dose ipamorelin infusion is required to fully restore gut function after surgery** — a single bolus only partially addresses POI by accelerating initial transit without correcting the broader recove…
**Anti-doping laboratories now have a validated, multi-analyte LC-MS protocol** covering the eight most relevant GHRP candidates in a single urine assay, filling a critical gap left by GH immunoassays. The 20 h metabo…
This advanced analytical method provides a crucial tool for anti-doping agencies to combat the illicit use of GHRPs in both equine and human sports. By enabling reliable and high-throughput detection, it helps ensure …
These findings directly inform and improve anti-doping testing protocols. By identifying specific, long-lasting metabolites for each GHRP, labs can create more robust screening methods that significantly extend the de…
This research provides a foundational understanding of which structural parts of GHRPs like Ipamorelin are critical for their function. For peptide users, this knowledge explains why certain analogues are more or less…
This research reveals the specific chemical modifications being made to performance-enhancing drugs on the black market, providing critical intelligence for anti-doping agencies. The discovery of a 192-amino-acid GH v…
This groundbreaking discovery represents a significant new challenge for global anti-doping agencies and laboratories, as these glycine-modified GHSs are unlikely to be detected by current, standard screening protocol…
This research provides a proof-of-concept for a sophisticated drug delivery system in oncology, specifically for Boron Neutron Capture Therapy. By successfully attaching a stable boron cluster to peptides like Ipamore…
For clinicians and individuals managing hypogonadism, this review positions GHS like ipamorelin as a potential next-frontier adjunctive therapy to testosterone, specifically for targeting body composition issues like …
For anti-doping analysts and forensic toxicologists, this study validates a practical and ethical method for identifying new biomarkers of peptide abuse. Instead of relying on difficult-to-conduct human trials, labs c…
For anti-doping agencies, this research provides a validated method to significantly increase the speed and efficiency of screening for peptides like the TB-500 fragment. The ability to process **up to 96 samples simu…
Free, no account — handy when you're working with GHRP-6.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account